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Abstract: Background: Immunization of patients with Alzheimer’s disease (AD) with synthetic amyloid- peptide (A42) 
(AN1792) was previously studied in a randomized, double-blind, placebo-controlled phase 2a clinical trial, Study 
AN1792(QS-21)-201. Treatment was discontinued following reports of encephalitis. One year follow-up revealed that 
AN1792 antibody responders showed improvements in cognitive measures as assessed by the neuropsychological test bat-
tery (NTB) and a decrease in brain volume compared with placebo. 
Methods: A follow-up study, Study AN1792(QS-21)-251, was conducted to assess the long-term functional, psychomet-
ric, neuroimaging, and safety outcomes of patients from the phase 2a study 4.6 years after immunization with AN1792. 
The results were analyzed by comparing patients originally identified as antibody responders in the AN1792 phase 2a 
study with placebo-treated patients. Results: One hundred and fifty-nine patients/caregivers (30 placebo; 129 AN1792) 
participated in this follow-up study. Of the 129 AN1792-treated patients, 25 were classified in the phase 2a study as anti-
body responders (anti-AN1792 titers 1:2,200 at any time after the first injection). Low but detectable, sustained anti-
AN1792 titers were found in 17 of 19 samples obtained from patients classified as antibody responders in the phase 2a 
study. No detectable anti-AN1792 antibodies were found in patients not classified as antibody responders in the phase 2a 
study. Significantly less decline was observed on the Disability Assessment for Dementia scale among antibody respond-
ers than placebo-treated patients (p=0.015) after 4.6 years. Significant differences in favor of responders were also ob-
served on the Dependence Scale (p=0.033). Of the small number of patients who underwent a follow-up MRI, antibody 
responders showed similar brain volume loss during the follow-up period subsequent to the AN1792 phase 2a study com-
pared with placebo-treated patients.  
Conclusions: Approximately 4.6 years after immunization with AN1792, patients defined as responders in the phase 2a 
study maintained low but detectable, sustained anti-AN1792 antibody titers and demonstrated significantly reduced func-
tional decline compared with placebo-treated patients. Brain volume loss in antibody responders was not significantly dif-
ferent from placebo-treated patients approximately 3.6 years from the end of the original study. No further cases of en-
cephalitis were noted. These data support the hypothesis that A immunotherapy may have long-term functional benefits. 
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INTRODUCTION 
  Alzheimer’s disease (AD) is a neurodegenerative disor-
der that represents the leading cause of dementia in the eld-
erly, with approximately 27 million AD patients worldwide. 
The global prevalence of AD is expected to quadruple to 
approximately 106 million patients by 2050 [1]. Treatment 
options to delay or halt the progression of AD to dementia 
are highly desirable. Immunotherapy with human amyloid- 
(A) 1-42 peptide (AN1792) stimulated the clearance of 
amyloid plaques and prevented AD-associated cognitive   
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decline in a mouse model of AD [2]. Efficacy observed after 
immunization with AN1792 in the mouse model led to the 
strategy of targeted A immunotherapy for removal and 
clearance of A from the brains of AD patients. 
  Preclinical studies in several species demonstrated the 
safety, tolerability, and activity of AN1792 in combination 
with the adjuvant QS-21 [2-6]. Phase 1 studies demonstrated 
that the optimal dose combination for eliciting an anti-
AN1792 antibody response was AN1792 225 g and QS-21 
50 g [7]. Accordingly, a double-blind, placebo-controlled, 
multi-center phase 2a study (Study 201) was initiated to 
evaluate the safety, tolerability, and pilot efficacy of 
AN1792 in patients with mild-to-moderate AD. Study drug 
administration was discontinued in January 2002 after the 
first reports of meningoencephalitis [8]. The protocol was 
amended to monitor all patients for 12 months from the first 
dose of drug, while maintaining the study blind to determine Long-Term Follow-Up of Patients Immunized with AN1792  Current Alzheimer Research, 2009, Vol. 6, No. 2    145 
the safety and tolerability of AN1792. Efficacy measures 
continued to be assessed. 
  At the end of the 1-year follow-up assessments in the 
phase 2a study, AN1792-treated patients who were antibody 
responders (anti-A titers 1:2,200) showed improvements 
in cognitive measures as assessed by a 9-component neuro-
psychological test battery (NTB) z-score, a composite of 
tests assessing memory and executive function. Furthermore, 
antibody responders showed a reduction in cerebrospinal 
fluid (CSF) tau levels compared with placebo-treated pa-
tients, which suggested a reduced level of neurodegeneration 
compared with baseline [9]. Volumetric brain MRI results 
revealed a decrease in whole brain volume (WBV) and an 
increase in ventricular volume in antibody responders com-
pared with placebo-treated patients. Interestingly, despite the 
greater loss of brain volume, antibody responders maintained 
a cognitive advantage compared with placebo-treated pa-
tients, implying that the extra brain volume reduction seen in 
the responders was not due to neuronal loss [10]. Autopsy of 
4 patients who were treated with AN1792 (2 with encephali-
tis and 2 without encephalitis) showed evidence of amyloid 
plaque clearance [11-13].
 
  This follow-up study (Study 251) was designed to evalu-
ate whether those patients who were antibody responders in 
the phase 2a study had altered clinical outcomes or rates of 
brain atrophy after long-term follow up in the absence of 
treatment compared with placebo-treated patients. Evidence 
of clinical benefit would provide further support for A im-
munotherapy as a potential treatment approach in AD.  
METHODS 
Patients 
  Patients were required to have participated in the phase 
2a study and to have provided appropriate written informed 
consent to participate in the follow-up analysis [9]. Patients 
eligible for entry to the phase 2a study were 50 to 85 years of 
age, met the criteria for a diagnosis of probable AD as de-
fined by the National Institute of Neurologic and Communi-
cative Disorders and Stroke–AD and Related Disorders As-
sociation, and had an MRI brain scan supporting the clinical 
diagnosis of AD. Additional inclusion criteria were a score 
of 15 to 26 on the Mini-Mental State Examination (MMSE), 
a Rosen-Modified Hachinski Ischemic score of 4, and writ-
ten informed consent from the patient and the patient’s care-
giver for the original protocol and subsequent amendments. 
Patients were excluded if they had clinically significant neu-
rologic disease (other than AD) that might affect cognition, a 
major psychiatric disorder, systemic illness or symptoms that 
could affect the patient’s ability to complete the study, a 
Hamilton Psychiatric Rating Scale for Depression (17 item) 
score of >12, used anticonvulsant, antiparkinsonian, antico-
agulant, narcotic, or immunosuppressive medication within 3 
months prior to baseline, used medication with the potential 
to affect cognition (unless maintained on a stable low-to-
moderate–dose regimen for at least 3 months prior to base-
line), or used medication for cognitive enhancement other 
than a stable dosing regimen of an acetylcholinesterase in-
hibitor (6 months). 
 
Study 201 Design and Treatment 
  This randomized, placebo-controlled, double-blind, phase 
2a clinical trial, reported by Gilman and colleagues in 2005, 
was conducted at 28 centers in the United States and Europe 
between September 2001 and December 2002 [9]. A total of 
372 patients with mild-to-moderate AD were randomly as-
signed in a double-blind manner to receive treatment with a 
suspension of AN1792 225 g (Elan Pharmaceuticals, Inc., 
South San Francisco, CA) and QS-21 50 g (Antigenics, 
Framingham, MA) containing 0.4% polysorbate-80, or nor-
mal saline (placebo) in a 4:1 ratio. A 6-member independent 
Data Safety Monitoring Committee assessed the safety of the 
study drug throughout Study 201. 
  In each group, treatment was administered as a single 0.5 
mL intramuscular (IM) injection and dosing was to occur on 
Day 0 and at Months 1, 3, 6, 9, and 12 according to the 
original protocol. Due to the early discontinuation of the 
immunization, patients received only 1 to 3 injections [9]. 
All patients enrolled in the study (including those who dis-
continued early) were invited to participate in the safety fol-
low-up period, which continued blinded and lasted until 
Month 12 (ie, at least 9 months after their last dose of study 
treatment).  
Follow-Up Study 251 Design 
  This was a multi-center out-patient follow-up study in 
patients with AD who had participated in the phase 2a study 
described above [9]. The follow-up study was conducted at 
23 centers in the United States and Europe between January 
and October 2006. No study medication was dispensed in 
this follow-up study. 
  An initial telephone contact was made to assess interest 
in participation. Subsequently, a clinic visit was conducted 
after obtaining informed consent. At this visit, a blood sam-
ple to assess serum anti-AN1792 antibody titers and plasma 
A concentration was collected. The following functional 
and cognitive assessments were performed: Disability As-
sessment for Dementia (DAD), Dependence Scale, Clinical 
Dementia Rating–Sum of Boxes (CDR-SOB), MMSE, NTB, 
and Alzheimer’s Disease Assessment Scale Cognitive Sub-
scale (ADAS-Cog). A volumetric brain MRI scan was also 
performed. Changes in the patients’ living situation since the 
beginning of the phase 2a study were queried. Any serious 
adverse events (SAEs) that occurred after the last visit in the 
initial phase 2a study were assessed, and the relationship to 
study drug was determined by the investigator.  
  A home visit or telephone contact, in lieu of the clinic 
visit, was conducted if the patient could not attend the clinic. 
In these patients, the DAD, Dependence Scale, CDR-SOB, 
and questions regarding changes in living situation were ad-
ministered over the telephone. The telephone contact was 
also used to collect patient information regarding any SAEs 
that may have occurred since the previous phase 2a study. 
Antibody titers were not assayed and follow-up MRIs were 
not conducted in this group that could not attend clinic.  
  The clinical raters performing the cognitive and func-
tional instruments in the AN1792-251 follow up study per- 
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formed these tests without knowledge of the patient’s group 
assignment or antibody status. Patients and caregivers were 
given access to treatment assignment upon request at the end 
of the AN1792-201 phase 2a study, however, they were not 
provided information regarding whether they were antibody 
responders or nonresponders.  
  Site-specific, local, independent ethics committees ap-
proved the protocol, amendments, and related informed con-
sent forms prior to implementation of each study. The stud-
ies were conducted in accordance with the International Con-
ference on Harmonization Tripartite Guidelines on Good 
Clinical Practice and in compliance with the Declaration of 
Helsinki 1964 as modified in October 2000.  
Study 251 Outcome Measures and Statistical Analyses 
  An enzyme-linked immunosorbent assay (ELISA) was 
used to determine total anti-AN1792 immunoglobulin (Ig)G 
levels in follow-up study baseline serum samples. The 
ELISA had a lower limit of detection of 1:50 for serum IgG. 
Patients who achieved a serum anti-AN1792 titer 1:2,200 
any time after the first injection in the phase 2a study were 
considered antibody responders. A titer 1:2,200 was prese-
lected as the minimum threshold anti-AN1792 titer likely to 
be of significant clinical benefit, based on preclinical data 
(Elan Pharmaceuticals, Inc., data on file). 
Functional, Dependence, and Global Endpoints 
  The DAD scale was administered to caregivers to meas-
ure the patients’ performance of instrumental and basic ac-
tivities of daily living over a 2-week period before the 
scheduled follow-up visit [14]. For each activity, questions 
were asked to evaluate the patients’ performance on initia-
tion, planning and organization, and effectiveness. Change 
from phase 2a study baseline for the DAD score was ana-
lyzed using an analysis of covariance (ANCOVA) model 
with change from phase 2a study baseline DAD score as the 
response, study group (Study 201 antibody responder classi-
fication vs. placebo) as a factor, and phase 2a study baseline 
DAD score as a covariate. 
  The Dependence Scale [15], also completed by the care-
giver, asks 13 questions assessing the required amount of 
assistance or care from others needed by the patient. The 
scale is scored as a sum of items, with patients having the 
least degree of dependence scored a 0 and patients with the 
highest level of need receiving a 15. Comparisons of the 
total Dependence Scale scores in the follow-up study were 
performed using analysis of variance (ANOVA). 
  The CDR-SOB scale measures patient impairment due to 
cognitive loss by evaluating 6 categories or box scores: 
memory, orientation, judgment and problem solving, com-
munity affairs, homes and hobbies, and personal care [16]. 
The rating is based on interviews conducted with both the 
patient and the caregiver. Change from baseline for the 
CDR-SOB score was analyzed using an ANCOVA model 
with change from phase 2a study baseline CDR-SOB score 
as the response, study group as a factor, and phase 2a study 
baseline CDR-SOB score as a covariate. 
 
Cognitive Endpoints 
  The NTB was used to assess cognitive and executive 
function, and consisted of 6 memory tests (Wechsler Mem-
ory Visual Paired Associates–Immediate and Delayed Re-
call; Wechsler Memory Verbal Paired Associates–Immediate 
and Delayed Recall; Rey Auditory Verbal Learning Test–
Immediate and Delayed Recall) and 3 executive function 
tests (Wechsler Memory–Digit Span; Controlled Word As-
sociation Test [FAS]; Category Fluency Test [animals]) [17]. 
Raw scores on each of the 9 NTB tests were converted to z-
scores using the baseline means and standard deviations 
(SDs) of phase 2a study participants for each test. The resul-
tant z-scores were averaged to obtain a composite z-score, 
incorporating all 9 NTB tests. The NTB was further analyzed 
in subgroups of the overall composite NTB z-score, includ-
ing the all memory z-score (utilizing all 6 memory tests) and 
executive function z-score (utilizing the 3 executive function 
tests). Change from baseline was calculated as the post-
baseline composite z-score minus the phase 2a study base-
line score, such that a positive change indicates an improve-
ment from baseline. NTB scores were analyzed using an 
ANCOVA model with change from phase 2a study baseline 
NTB score as the response, study group as a factor, and 
phase 2a study baseline NTB score as a covariate.  
  In addition to the NTB, other cognitive endpoints in-
cluded the MMSE and the ADAS–Cog [18, 19]. Analysis of 
the MMSE and ADAS-Cog were handled similarly to the 
NTB, using an ANCOVA model with change from the phase 
2a study baseline score as the response, study group as a 
factor, and phase 2a study baseline score as a covariate.  
Additional Endpoints 
  Caregivers were queried as to where the patients lived at 
the start and finish of the phase 2a study and at the time of 
the follow-up study. The frequency and percentage of pa-
tients who remained in their own home or who entered a 
long-term care facility or nursing home from the beginning 
of the phase 2a study were determined.  
  Changes in brain, ventricular, and hippocampal volume 
were determined by MRI methods previously described [10]. 
Brain boundary shift integral was only calculated on scan 
pairs that did not have a significant acquisition change be-
tween time points. All decisions on patient suitability for 
scan acquisition or inclusion for analysis were made blind to 
treatment status. Similarly, all MRI measurements were per-
formed blind to treatment status. Change on MRI was evalu-
ated from baseline as well as from the final MRI visit in the 
phase 2a study (Month 12). In each case, as appropriate, the 
baseline volume or final MRI volume was included in the 
model as a covariate.  
Safety 
Information about SAEs that occurred since the end of the 
phase 2a study was collected and summarized. Patients’ vital 
status (ie, alive or dead) was also recorded and compared 
between treatment groups. 
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RESULTS 
Patients 
  Of 372 patients treated in the phase 2a study (300 active; 
72 placebo), a total of 264 (71.0%) patients/caregivers were 
contacted to determine interest in follow-up study participa-
tion. One hundred and fifty-nine patients/caregivers agreed 
to participate in the follow-up study (30 placebo; 129 treated 
with AN1792 + QS-21). Of the original 59 subjects who 
were classified in the phase 2a study as antibody responders 
(anti-AN1792 titers 1:2,200 at any time after the first injec-
tion), 25 (42.4%) agreed to participate in the follow-up study 
compared with 30/72 (41.7%) of the placebo-treated patients 
(Fig. 1). In addition, 104/241 (43.2%) of patients classified 
as low or non-responders from Study 201 were enrolled in 
this follow-up study; however, data gathered from these pa-
tients and caregivers are beyond the objectives and scope of 
the present communication. Patient demographics and base-
line characteristics were similar between antibody respond-
ers and placebo-treated patients at the start of this follow-up 
study (Table 1).  
  A substantial portion of patients and/or caregivers were 
not contacted for participation in this follow-up study. A 
number of patients not contacted were known to be dead or 
were lost to follow up. Similar numbers of patients/ caregiv-
ers were not able to be contacted in both the antibody re-
sponder group (n=19 [32.2%]) and the placebo group (n=22 
[30.6%]) (Table 1). Of the live patients and their caregivers 
who were contacted to participate in this follow-up study, 
fewer antibody responders refused to participate (8/39, or 
20.5%), compared with 15/48 (31.3%) of placebo-treated 
patients (Table 1). 
  The majority of patients enrolled in this follow-up study 
were taking concomitant acetylcholinesterase inhibitors or 
memantine. The proportion of patients taking concomitant 
medications was similar between antibody responders and 
placebo-treated patients. Twenty-two of 30 (73.3%) placebo-
treated patients were taking concomitant acetylcholinesterase 
inhibitors compared with 19/25 (76.0%) of antibody re-
sponders. Fifteen of 30 (50.0%) placebo-treated patients 
were taking concomitant memantine, compared with 15/25 
(60.0%) of antibody responders.  
  Mean time of follow up, either from baseline or from the 
final study visit in the original Phase 2a study to final as-
sessment in this analysis, was similar across treatment and 
response groups (Table 1).  
Immunologic Findings 
  Of the 300 patients randomized to receive AN1792 in the 
phase 2a study, 59 (19.7%) were classified as antibody re-
sponders (having total serum anti-AN1792 IgG titers 
1:2,200 at any time after the first injection)—25 of these 
antibody responders agreed to participate in this follow-up 
study. Of these participating antibody responders, 19 submit-
ted a blood sample for antibody testing. Seventeen of the 19 
tested antibody responders (89.5%) had a low but persistent 
residual mean anti-AN1792 antibody titer, with a geometric 
mean of 1:331.5 compared with non-detectable levels in all 
19 placebo-treated patients who submitted a blood sample 
(p<0.001). No detectable anti-AN1792 antibodies were 
found in patients not classified as antibody responders in the 
phase 2a study. Antibody responders retained low but persis-
tent levels of anti-AN1792 antibodies after approximately 
4.6 years despite receiving only 1 to 3 of the planned injec-
tions in the original Phase 2a study. 
Changes in Functional, Dependence, and Global Meas-
ures 
DAD 
  Caregivers provided DAD ratings for 27/30 placebo-
treated patients (90.0%) and 24/25 antibody responders 
 
 
 
 
 
 
 
 
 
 
 
Fig. (1). Disposition of patients classified as antibody responders and placebo-treated patients enrolled in Study 251. Patients were consid-
ered antibody responders in Study 201 if they had a serum anti-AN1792 IgG (total) titer 1:2,200 at any time after injection 1. 148    Current Alzheimer Research, 2009, Vol. 6, No. 2  Vellas et al. 
(96.0%). After approximately 4.6 years of follow up, anti-
body responders demonstrated a 25.0% lower decline in ac-
tivities of daily living as determined by the DAD compared 
with placebo-treated patients (mean change ± SD of -56.34 ± 
28.45 for placebo vs -42.28 ± 30.88 for antibody responders, 
p=0.015).  
Dependence Scale 
  Caregivers provided Dependence Scale ratings for 28/30 
placebo-treated patients (93.3%) and 24/25 antibody re-
sponders (96.0%). Antibody responders demonstrated a 
17.6% lower mean score in caregiver dependence compared 
with placebo-treated patients (mean score ± SD of 10.2 ± 2.6 
for placebo vs 8.4 ± 3.4 for antibody responders, p=0.033).  
CDR-SOB 
  CDR-SOB ratings were obtained for 24/30 placebo-
treated patients (80.0%) and 22/25 antibody responders 
(88.0%). Similar to the DAD and Dependence Scale, anti-
body responders from the phase 2a study showed 20.2% less 
decline on the CDR-SOB scale compared with placebo, al-
though this difference was not statistically significant (mean 
change ± SD of 7.63 ± 4.48 for placebo vs 6.09 ± 4.75 for 
antibody responders, p=0.185).  
Cognitive Function 
NTB 
  The NTB as well as the other cognitive instruments were 
only administered in follow up to those patients who were 
available for testing and capable of being tested on these 
instruments. At the time of the follow-up study, the NTB 
was attainable in only 10/30 placebo-treated patients (33.3%) 
and 13/25 antibody responders (52.0%). No significant dif-
ferences were observed in the change from baseline for the 
overall NTB 9-component z-score between antibody re-
sponders and placebo-treated patients (mean change ± SD of 
-0.751 ± 0.560 for placebo vs -0.597 ± 0.626 for antibody 
responders, p=0.440). Of the NTB z-score components, the 
Rey Auditory Verbal Learning Test – Delayed Recall com-
ponent showed reduced decline among antibody responders 
(mean change ± SD of -1.096 ± 1.165 for placebo vs 0.114 ± 
1.138 for antibody responders, p=0.046).  
MMSE and ADAS-Cog 
  An MMSE was attainable in 18/30 placebo-treated pa-
tients (60.0%) and 20/25 antibody responders (80.0%). No 
significant differences were observed between antibody re-
sponders compared with placebo-treated patients after 4.6 
years of follow up (mean change ± SD of -8.3 ± 5.8 for pla-
cebo vs -8.0 ± 7.8 for antibody responders, p=0.719).  
  The ADAS-Cog was attainable in 11/30 placebo-treated 
patients (36.7%) and 16/25 antibody responders (64.0%). No 
significant differences in ADAS-Cog score were observed 
between placebo-treated patients and antibody responders 
after approximately 4.6 years of follow up (mean change ± 
SD of 14.4 ± 14.2 for placebo vs 14.3 ± 14.0 for antibody 
responders, p=0.616).  
Table 1.  Patient Disposition and Demographics by Treatment and Response Group 
  Antibody Responder  Placebo-treated 
Patients enrolled in original Phase 2a Study 201 (n)  59  72 
Who died in Study 201(n [%])  1 (1.7)  2 (2.8) 
Patients or caregivers not contacted for participation in Study 251 (n [%])  19 (32.2)  22 (30.6) 
Known dead (n [%])  5 (8.5)  3 (4.2) 
Status unknown (n [%])  14 (23.7)  19 (26.4) 
Patients or caregivers contacted for participation in Study 251 (n [%])  39 (66.1)  48 (66.7) 
Dead, caregiver did not agree to participate (n [%])  6 (10.2)  3 (4.2) 
Alive, did not agree to participate (n [%])  8 (13.6)  15 (20.8) 
Dead, caregiver agreed to participate (n [%])  1 (1.7)  1 (1.4) 
Alive, agreed to participate (n [%])  24 (40.7)  29 (40.3) 
Total participation in Study 251, alive or dead (n [%])  25 (42.4)  30 (41.7) 
Mean time to follow up in Study 251 from baseline in original Phase 2a Study 201 ± SD (years)   4.63 ± 0.12  4.61 ± 0.10 
Mean time to follow up in Study 251 from end of original Phase 2a Study 201 ± SD (years)   3.66 ± 0.14   3.63 ± 0.14  
Mean age ± SD (years), start of Study 251  74.9 ± 7.32  73.7 ± 8.65 
Phase 2a Study 201 baseline mean MMSE ± SD, (n)  21.0 ± 3.3
 (24)  19.8 ± 2.8
 (29) 
ApoE4 carriers, n (%)   20 (80.0)
  17 (56.7)
 
Note: The denominators for patient disposition percentages are the numbers of patients enrolled in the original Phase 2a Study 201. The denominators for ApoE4 carrier percentages 
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Changes in Living Situation 
  Changes in living situation were available for all partici-
pating subjects in the follow-up study. After approximately 
4.6 years, 19/25 (76.0%) antibody responders remained in 
their own home compared with 16/30 (53.3%) placebo-
treated patients (p=0.099). Similarly, only 4/25 (16.0%) an-
tibody responders were in long-term care institutions after 
approximately 4.6 years compared with 9/30 (30.0%) pla-
cebo-treated patients (p=0.341).  
MRI Brain Volume Analysis 
  Patients who were antibody responders in the phase 2a 
study demonstrated increased WBV loss compared with pla-
cebo-treated patients, with no associated increase in cogni-
tive decline [10]. This follow-up study compared changes in 
brain volume measurements between antibody responders 
and placebo-treated patients from the last visit in the phase 
2a study with those observed at the time of the follow-up 
study visit. MRIs were available for 8/30 (26.7%) placebo-
treated patients and 8/25 (32.0%) antibody responders. From 
the time of the last MRI in the original phase 2a study, anti-
body responders demonstrated no significant differences in 
WBV loss compared with placebo-treated patients (mean 
percent change ± SD of -5.11% ± 3.96% for placebo vs -
5.66% ± 2.62% for antibody responders, p=0.854). No sig-
nificant difference on brain boundary shift integral (mean 
percent change ± SD of 4.69% ± 2.36% for placebo vs 
6.61% ± 2.86% for antibody responders, p=0.211) was ob-
served; however, because of changes in scan acquisition, the 
boundary shift integral was only available for 7 placebo-
treated patients and 6 antibody responders. There was also 
no significant difference in the percentage increase in ven-
tricular volume, expressed as a percentage of baseline whole-
brain volume, between placebo-treated patients and antibody 
responders (mean percent change ± SD of 1.25% ± 0.70% 
for placebo vs 2.00% ± 0.88% for antibody responders, 
p=0.285) after 3.6 years from the last MRI in the phase 2a 
study. Similarly, there was no significant difference in either 
left hippocampal loss (mean percent change ± SD of -
12.44% ± 8.78% for placebo vs -15.28% ± 7.62% for anti-
body responders, p=0.436) or right hippocampal loss (mean 
percent change ± SD of -10.57% ± 7.58% for placebo vs -
13.51% ± 5.74% for antibody responders, p=0.402). 
  This follow-up study also compared changes in brain 
volume measurements between antibody responders and 
placebo-treated patients from the baseline MRI in the phase 
2a study with those observed at the time of the follow-up 
study. MRI scan pairs were available for 7/30 (23.3%) pla-
cebo-treated patients and 8/25 (32.0%) antibody responders 
at baseline. Antibody responders demonstrated no significant 
differences in WBV loss compared with placebo-treated pa-
tients after approximately 4.6 years from the first MRI per-
formed in the original phase 2a study (mean percent change 
± SD of -6.24% ± 4.58% for placebo vs -7.94% ± 1.70% for 
antibody responders, p=0.383). Brain boundary shift integral 
measures were available for 6 placebo-treated patients and 5 
antibody responders, and demonstrated no significant differ-
ence (mean percent change ± SD of 5.10% ± 2.70% for pla-
cebo vs 8.48% ± 3.81% for antibody responders, p=0.119). 
Similarly, there was no significant difference in either left 
hippocampal loss (mean percent change ± SD of -13.54% ± 
8.47% for placebo vs -17.03% ± 8.76% for antibody re-
sponders, p=0.346) or right hippocampal loss (mean percent 
change ± SD of -10.86% ± 6.49% for placebo vs -14.74% ± 
5.92% for antibody responders, p=0.164). However, a sig-
nificant difference in ventricular volume enlargement, ex-
pressed as a percentage of baseline whole-brain volume, was 
observed from baseline after approximately 4.6 years in this 
subgroup of patients with MRI follow up (mean percent 
change ± SD of 1.39% ± 0.82% for placebo vs 2.83% ± 
1.29% for antibody responders, p=0.021). 
Safety 
  Patients and caregivers who enrolled in the follow-up 
study were asked to provide information on any SAEs that 
occurred from the time of their final visit in the phase 2a 
study. There was a similar overall incidence of SAEs for 
placebo-treated patients (33.3%) compared with antibody 
responders (40.0%). No SAEs were considered by the inves-
tigator to be related to AN1792. No cases of encephalitis 
were reported in this follow-up study. No deaths were con-
sidered related to study drug by the investigator. Vital status 
information was available for 53/72 (73.6%) of placebo-
treated patients and 45/59 (76.3%) antibody responders who 
were participants in the original phase 2a study. Survival was 
not significantly different between antibody responders and 
placebo-treated patients. For subjects in whom vital status 
information was available, 44/53 (83.0%) placebo-treated 
patients remained alive compared with 32/45 (71.1%) of 
antibody responders (p=0.220). 
DISCUSSION 
  The comparisons conducted in this AN1792 follow-up 
study were performed between patients classified as anti-
body responders and those treated with placebo in the origi-
nal phase 2a study. The prospectively defined goal of these 
analyses was to determine if benefits might accrue over time 
in patients who developed prospectively defined antibody 
titers (1:2,200) that were considered adequately therapeutic 
in the phase 2a study. 
 
  This follow-up study suggests that 1 to 3 doses of 
AN1792 administered to patients with mild-to-moderate AD 
may have had long-term clinical benefits in patients who 
developed anti-AN1792 antibodies. Patients classified as 
antibody responders at the end of the phase 2a study retained 
low but persistent anti-AN1792 antibody titers after ap-
proximately 4.6 years. Compared with placebo-treated pa-
tients, antibody responders demonstrated significantly less 
impairment in activities of daily living and significantly less 
dependence on caregivers. A higher percentage of antibody 
responders remained at home and a lower percentage were 
institutionalized. These results provide further support for 
the A immunotherapeutic approach in patients with mild-
to-moderate AD. 
  In contrast to testing of functional and dependence meas-
ures (for which caregiver assessments were available for the 
majority of participating subjects), fewer assessments of 
cognitive outcomes (including the NTB, MMSE, and 
ADAS-Cog) were able to be performed, as patients became 
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tion due to disease progression. For all cognitive outcomes, 
there were relatively fewer placebo-treated patients eligible 
for cognitive testing than antibody responders. Therefore, 
comparisons of cognitive function in this follow-up study 
may not be representative of the entire placebo-treated 
group, and may favor the assessment of placebo-treated pa-
tients who were less impaired and capable of undergoing 
cognitive testing. Despite this potential bias to include bet-
ter-performing placebo-treated patients in the cognitive 
analyses, antibody responders tended to perform better on 
the memory component of the NTB. They demonstrated sig-
nificantly less decline on a memory subtest of the NTB (Rey 
Auditory Verbal Learning Test – Delayed Recall) and simi-
lar declines compared with placebo on the other cognitive 
outcomes. 
 
  A similar overall incidence of SAEs for placebo-treated 
patients compared with antibody responders was observed. 
No SAEs were considered by the investigator to be treatment 
related. Although dosing in the phase 2a study was halted 
after 18 patients (6.0%) developed encephalitis, no new 
cases of encephalitis were reported after 4.6 years in this 
follow-up study, and similar survival was observed between 
treatment groups. 
  Antibody responders in the phase 2a study demonstrated 
increased brain volume loss and increased ventricular en-
largement over 11 months of follow up. In the small sample 
of patients who had MRI scans in this follow-up study, brain 
volume loss in antibody responders from the time of the last 
phase 2a study visit was similar to changes observed in pla-
cebo-treated patients. Ventricular enlargement was still sig-
nificantly greater in antibody responders when compared 
with baseline measurements in the phase 2a study, but not 
when compared with the final scan. When compared with the 
final scan performed in the original study we were not able 
to show significant differences between antibody responders 
and placebo-treated patients on any MRI measures (whole 
brain or hippocampal loss and ventricular enlargement). It is 
tempting to speculate that rates of loss were similar between 
the two groups after the end of the phase 2a study; however, 
due to the small numbers of subjects, the study had very lim-
ited power to detect any such differences. Although firm 
conclusions cannot be drawn, this suggests that there contin-
ues to be dissociation, as observed in our original report, of 
better cognitive or functional performance despite greater 
brain volume loss [10]. This implies that whatever accounted 
for the increased loss on MRI measures it was not neuronal 
degeneration. 
  Results from a phase 1 study of patients with mild-to-
moderate AD treated with AN1792 demonstrated reduction 
in functional decline as measured by DAD that did not reach 
statistical significance until approximately 20 months [7]. 
The phase 2a study represents an independent patient group 
treated with AN1792. Differences in DAD score between 
antibody responders and placebo-treated patients similarly 
did not reach significance at 1 year, but did eventually show 
statistically significant differences after 4.6 years [9]. This 
finding is particularly noteworthy because only residual low 
titers were observed after long-term follow up. One obvious 
question this follow-up study raises is what clinical effects 
might have been observed had antibody responders retained 
a higher antibody titer (ie, 2,200) over the length of follow 
up. 
  The NTB scale, comprised of 9 well-known and vali-
dated cognitive tests, was utilized in the previous AN1792 
phase 2a study [9, 17]. In the follow-up study reported here, 
a greater percentage of antibody responders performed the 
NTB than placebo-treated patients. Similarly, relatively 
fewer placebo-treated patients were administered the ADAS-
Cog and MMSE compared with antibody responders. No 
apparent benefits were detected in antibody responders com-
pared with placebo-treated patients among the testable sub-
jects on the ADAS-Cog or MMSE. It is possible that amy-
loid-targeted immunotherapies have a greater effect on the 
retention of memory-related functions than on other cogni-
tive domains. Alternatively, the lack of benefit seen on the 
MMSE and ADAS-Cog may be confounded if only the less 
impaired placebo-treated patients capable of undergoing 
cognitive testing were assessed. The latter explanation is 
supported by the significant treatment effects seen on the 
DAD and Dependence Scale in whom data on more patients 
was available. 
  A limitation of this study was that only a small propor-
tion of the subjects could be reassessed this long after the 
start of the original phase 2a study; the proportion that could 
be restudied with MRI was inevitably even smaller. None-
theless, it is interesting to note that after approximately 4.6 
years, patients classified as responders to initial therapy with 
AN1792 retained detectable levels of anti-AN1792 antibody. 
Moreover, antibody responders demonstrated functional and 
dependence benefits compared with placebo-treated patients, 
with comparable safety and survival observed between 
treatment groups. No SAEs were considered treatment re-
lated, and no additional cases of encephalitis were reported. 
Placebo-treated patients and antibody responders did not 
demonstrate significant differences in loss of brain volume 
approximately 3.6 years from the end of the phase 2a study. 
These studies suggest that A remains a valid target for the 
treatment of mild-to-moderate AD, demonstrating that 
strategies to reduce A may have the potential to sustain 
important clinical benefits in patients with AD. A number of 
different immunotherapeutic approaches to the treatment of 
AD are currently being studied.  
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